George Tidmarsh, a Stanford University physician who founded Horizon Pharma and later ran La Jolla Pharma, was named head of ...

Analysts questioned whether the complete response letter Replimune received was evidence of changing approval standards at ...

The French pharma will pay $1.15 billion upfront to buy Vicebio and gain access to non-mRNA vaccine candidates against RSV, ...

Experts on the panel shared many of the same views around SSRIs, arguing that the risks of the drugs during pregnancy are greater than currently accepted.

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Company CEO Doug Ingram said the pause was necessary for Sarepta to maintain a "productive and positive working relationship" ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

Conversations with the Trump administration on its “most favored nation” policy have been productive, the executive said ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...